Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings.

PURPOSE: To assess the safety and efficacy of the EyeMax Mono (SharpView Ophthalmology) extended macular vision intraocular lens (IOL), in patients with age-related macular degeneration (AMD) undergoing cataract surgery.

METHODS

This retrospective multicentre study analyzed real-world data from 196 AMD eyes (146 patients) across 15 medical centres in Europe. All eyes received the single-piece, hydrophobic acrylic, EyeMax Mono IOL. AMD severity was classified by the centre. Outcomes included intraoperative and postoperative complications and changes in corrected distance and near visual acuity (CDVA and CNVA, respectively).

RESULTS

The postoperative spherical equivalent was + 1.25 ± 1.32 D. Postoperative LogMAR CDVA improved significantly from a baseline of 0.57 ± 0.38 to 0.38 ± 0.34 (n = 191, p < 0.001), while CNVA improved from 0.49 ± 0.32 at baseline to 0.35 ± 0.27 postoperatively (n = 141, p < 0.001). 63% gained > 1 line of CDVA and 27.5% gained ≥ 3 lines. For CNVA, 41.5% gained > 1 line, and 21.8% gained ≥ 3 lines. The greatest gains occurred in intermediate AMD eyes: CDVA + 0.21 logMAR, CNVA + 0.12 logMAR. Only 2.1% of eyes lost > 1 line of CDVA or CNVA.

CONCLUSIONS

The EyeMax Mono intraocular lens (IOL) safely enhances both distant (CDVA) and near (CNVA) visual acuity in patients with age-related macular degeneration, particularly in eyes with intermediate AMD. These findings are consistent with those in the published scientific literature.